Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Ultrasound, Multilevel Erector Spinae Pl...
Phase NA
Enrollment 44
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to compare the analgesic efficacy of multilevel erector spinae plane block (ESPB) vs thoracic epidural in modified radical mastectomy (MRM) regarding duration of analgesia, postoperative opioid consumption, effect on intraoperative fentanyl consumption, postoperative numerical pain rating scale and quality of life for the next 6 months.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Erector spinae plane block (ESPB) — Erector spinae plane block (ESPB) using multilevel injections of bupivacaine 0.25%. We will inject 15ml at the level of T2 and 15ml at the level of T5.
  • Drug: Thoracic epidural block — Thoracic epidural block at level of T5 -T6 using 10 ml of bupivacaine 0.25% as a bolus followed by 5 ml bupivacaine 0.25% every 1-2 hours depending on the duration of surgery and the response of the patient.

Primary Outcomes

  • The average duration of analgesia (24 hours postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-20
Completion: 2026-03-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 44 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute, Egypt
Contact Information
Study Contact:
Ahmed El Abdelaal, Master
00201097900275
drahmedsayeh9915@gmail.com
Ahmed El Abdelaal, Master
00201097900275
drahmedsayeh9915@gmail.com
National Cancer Institute
Ghada G Elsayed, MD
National Cancer Institute
Interventions
  • Drug: Erector spinae plane block (ESPB) — Erector spinae plane block (ESPB) using multilevel injections of bupivacaine 0.25%. We will inject 15ml at the level of T2 and 15ml at the level of T5.
  • Drug: Thoracic epidural block — Thoracic epidural block at level of T5 -T6 using 10 ml of bupivacaine 0.25% as a bolus followed by 5 ml bupivacaine 0.25% every 1-2 hours depending on the duration of surgery and the response of the patient.
Study Locations (1 sites)
National Cancer Institute, Cairo, 11796 Egypt
Eligibility Criteria
Inclusion Criteria: * Female patients age ≥ 18 years and ≤ 65 Years. * Type of surgery; Modified Radical Mastectomy (MRM) * Physical status ASA II, III. * Body mass index (BMI): \> 20 kg/m2 and \< 35 kg/m2. Exclusion Criteria: * Patient refusal. * Allergy or a contraindication to the drug used in the study, e.g. local anesthetics, opioids. * History of psychological disorders. * History of chronic pain. * Contraindication to regional anesthesia e.g. sepsis, peripheral neuropathies and coagulopathy. * Advanced chronic renal disease, which is defined as a chronic kidney disease (CKD) in which there is a severe reduction in glomerular filtration rate (GFR \< 30 ml/min) and includes stages 4 and 5 of the CKD classification. * Decompensated cirrhosis, which is defined as an acute deterioration in liver function in a patient with cirrhosis and is characterized by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome, or variceal hemorrhage. * Severe heart disease which is defined as NYHA class iii (moderate symptoms with less than normal activity, marked limitation of function status) or NYHA class IV (severe symptoms with features of heart failure with minimal activity or at rest and severe limitation of functional status) * Severe lung disease which includes oxygen saturation of blood less than 92%, RR more than 20, FEV1/FVC ratio less than 60%. * Pregnancy.
Conditions Intimate Partner Violence (IPV)
Phase NA
Enrollment 172
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to improve treatment for Veterans Health Administration (VHA) patients who experience intimate partner violence (IPV). This study will evaluate two brief counseling interventions for VHA patients who have experienced IPV in the past 12 months: Recovering from IPV through Strength and Empowerment (RISE) and advocacy-based Enhanced Care as Usual (ECAU). The RISE intervention includes up to 8 sessions and includes specific topic areas (e.g., social support, health effects, resources). The other intervention, ECAU, includes a single session that includes supportive education about IPV and health effects, discussion of ways to increase safety, and information about resources. This study will test which approach is better for improving self-efficacy and other aspects of health. Participants will answer surveys about their self-efficacy and other health and safety indicators (e.g., mental health symptoms) right before receiving treatment, approximately 12 weeks later, and then every three months after that for one year. Participation in this research will last about 15 months.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: RISE — RISE is personalized, trauma-informed, empowerment-oriented and variable-length, consisting of an initial 60-minute session and up to 7 additional 45-minute sessions (1-8 sessions total).
  • Behavioral: Advocacy-based ECAU — Advocacy-based ECAU is a single 60-minute trauma-informed counseling intervention that includes supportive education, validating and empathetic statements, safety planning, resource provision and referrals.

Primary Outcomes

  • Self-efficacy (Baseline, 3 months, 6 months. 9 months, 12 months, 15 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-15
Completion: 2030-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 172 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Boston University
Collaborators: VA Boston Healthcare System, VA Philadelphia Healthcare System, VA Minnesota Healthcare System, Patient-Centered Outcomes Research Institute
Principal Investigators:
  • Katherine M Iverson, PhD (PRINCIPAL_INVESTIGATOR) - V Boston Healthcare System, BU CASchool Medicine Psychiatry
  • Melissa Dichter, PhD MSW (PRINCIPAL_INVESTIGATOR) - VA Philadelphia Healthcare System
Contact Information
Study Contact:
Katherine M Iverson, PhD
857-364-2066
Katherine.Iverson@va.gov
Julianne Brady
Julianne.Brady@va.gov
Katherine M Iverson, PhD
VA Boston Healthcare System
Interventions
  • Behavioral: RISE — RISE is personalized, trauma-informed, empowerment-oriented and variable-length, consisting of an initial 60-minute session and up to 7 additional 45-minute sessions (1-8 sessions total).
  • Behavioral: Advocacy-based ECAU — Advocacy-based ECAU is a single 60-minute trauma-informed counseling intervention that includes supportive education, validating and empathetic statements, safety planning, resource provision and referrals.
Study Locations (3 sites)
VA Boston Healthcare System, Boston, Massachusetts 02130 United States
VA Minneapolis Healthcare System, Minneapolis, Minnesota 55417 United States
VA Philadelphia Healthcare System, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Inclusion Criteria: * patients receiving care at an enrolled site/affiliated Community-Based Outpatient Clinic (CBOC) * report experience of past-year physical, psychological, and/or sexual IPV on an established screening tool used to detect IPV in VHA, and * be able to provide informed consent including permission to have intervention sessions recorded Exclusion Criteria: * severe cognitive impairment, * suicide or homicide intent with a specific plan * untreated or unstable symptoms of mania or psychosis
Conditions Schizophrenia, Schizoaffective Disorder,...
Phase NA
Enrollment 119
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Over 60% of Veterans with serious mental illness have a service-connected disability that impairs their ability to work, go to school, and/or have successful personal lives. Although traditional treatments tend to focus on symptom remission, Veterans prioritize a range of treatment goals, including personal empowerment and gaining personally meaningful skills. Increasing Veteran-clinician collaboration can help effectively align care with each Veteran's goals and support an empowering therapeutic experience. This project will evaluate the effectiveness of a group-based intervention intended to increase Veterans' comfort, confidence, knowledge, and skills to collaborate with their treatment teams. Findings from this study will contribute important knowledge about this intervention's effectiveness and how to enhance its effectiveness, especially for Veterans from minoritized groups. If the decision-making intervention is effective, it would help Veterans with serious mental illness, and might also help Veterans with other chronic health conditions, like PTSD and chronic pain.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Collaborative Decision Skills Training — An ten-session group-based skills training intervention that focuses on treatment-related decision-making in order to facilitate improved engagement in decision-making processes. CDST teaches assertiveness skills, problem solving, goal planning, and conflict negotiation, within the context of treatment planning and decision-making. Each session is 60 minutes long.
  • Behavioral: Leveling Up — An ten-session group intervention that focuses on psychoeducation, befriending, and Veteran to Veteran support. Each session is 60 minutes long.

Primary Outcomes

  • Shared Decision-Making Coding System (Baseline to 3-month follow-up)
  • Shared Decision-Making Coding System (Baseline to 6-month follow-up)
  • Consumer-Created Opportunities for Active Involvement Coding System (Baseline to 3-month follow-up)
  • Consumer-Created Opportunities for Active Involvement Coding System (Baseline to 6-month follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-12
Completion: 2029-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 119 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Principal Investigators:
  • Emily Treichler, PhD (PRINCIPAL_INVESTIGATOR) - VA San Diego Healthcare System, San Diego, CA
Contact Information
Study Contact:
Emily Treichler, PhD
(858) 552-8585
Emily.Treichler@va.gov
Emily Treichler, PhD
(858) 552-8585
Emily.Treichler@va.gov
VA San Diego Healthcare System, San Diego, CA
Emily Treichler, PhD
VA San Diego Healthcare System, San Diego, CA
Interventions
  • Behavioral: Collaborative Decision Skills Training — An ten-session group-based skills training intervention that focuses on treatment-related decision-making in order to facilitate improved engagement in decision-making processes. CDST teaches assertiveness skills, problem solving, goal planning, and conflict negotiation, within the context of treatment planning and decision-making. Each session is 60 minutes long.
  • Behavioral: Leveling Up — An ten-session group intervention that focuses on psychoeducation, befriending, and Veteran to Veteran support. Each session is 60 minutes long.
Study Locations (3 sites)
VA San Diego Healthcare System, San Diego, CA, San Diego, California 92161-0002 United States
VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California 90073-1003 United States
New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico 87108-5153 United States
Eligibility Criteria
Inclusion Criteria: 1. Be a Veteran currently receiving Psychosocial Rehabilitation and Recovery Center (PRRC), Mental Health Intensive Case Management (MHICM) and/or Behavioral Health Interdisciplinary Program (BHIP) services at VA San Diego, Los Angeles, or Albuquerque (e.g., seen in the clinic in the past month or based on clinic criteria) 2. Meet Substance Abuse and Mental Health Services Administration (SAMHSA) criteria of serious mental illness; i.e., "having (within the past year) a diagnosable mental, behavior, or emotional disorder that causes serious functional impairment that substantially interferes with or limits one or more major life activities," based on chart review and clinician consultation if needed 3. Be fluent and literate in English 4. Agree to have a subset of VA mental health treatment appointments audiotaped Exclusion Criteria: 1. Primary substance use or organic neurological disorder diagnosis determined by chart review 2. Are determined by clinician and/or study staff to be at significant risk of exacerbation of symptoms, suicidal ideation, or other risk due to study participation 3. Have a history and/or current risk of violence that clinicians and/or study staff determine to be too high risk to manage effectively in the study setting (e.g., poses a risk to Veterans or study staff)
Conditions Breast Cancer, Breast Cancer, HER2-Expre...
Phase Not Applicable
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the clinical utility of 18F-labeled HER2 Affibody PET for diagnosing and monitoring HER2-expressing breast cancer. HER2, a protein overexpressed in certain malignancies including breast cancer, serves as a critical biomarker for targeted therapies.The HER2 Affibody-an engineered 7 kDa protein with nanomolar affinity for HER2-leverages its rapid tumor penetration and clearance kinetics to achieve high-contrast PET imaging. This study aims to evaluate the diagnostic efficacy of 18F-HER2 Affibody PET in early detection, clinical staging, and treatment response monitoring, thereby providing novel imaging evidence to guide personalized therapeutic strategies for patients with HER2-expressing breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Radiation: 18F-HER2 Affibody PET scan — HER2 Affibody, labeled with PET radio-nuclide 18F will be used as a molecular imaging tracer for PET scan. All participants will undergo 18F-HER2 Affibody PET scan.

Primary Outcomes

  • SUV (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-04-09
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Affiliated Hospital of Qingdao University
Contact Information
Study Contact:
Zhenguang Wang, Doctoral Degree
+86-0532-82913318
wangzhenguang@qdu.edu.cn
Interventions
  • Radiation: 18F-HER2 Affibody PET scan — HER2 Affibody, labeled with PET radio-nuclide 18F will be used as a molecular imaging tracer for PET scan. All participants will undergo 18F-HER2 Affibody PET scan.
Study Locations (1 sites)
Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000 China
Eligibility Criteria
Inclusion Criteria: * Age 18-75 years, ECOG score 0 or 1. * Clinically or pathologically confirmed diagnosis of patients with HER2 expression breast cancer or suspected expression breast cancer. * Life expectancy ≥ 12 weeks. * At least one measurable target lesion according to RECIST 1.1 criteria. * All participants of reproductive potential (regardless of gender) must commit to using effective contraceptive methods throughout the trial participation and for 6 months after the last PET scan. * Ability to understand and voluntarily sign the informed consent form, with good compliance. Exclusion Criteria: * Severe hepatic or renal dysfunction. * Pregnant or lactating women, or women planning to become pregnant. * Inability to lie supine for half an hour. * Refusal to participate in this clinical study. * Suffering from claustrophobia or other mental illnesses. * Other conditions that the investigator deems unsuitable for participation in the trial.
Conditions Hypertension, Type 2 Diabetes Mellitus (...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

People with high blood pressure and diabetes often have low levels of key nutrients as a result of not eating enough fresh fruits and vegetables. Research studies suggest that these nutrients can lower blood pressure and blood sugar. This study will investigate if providing encouragement to adopt this healthy and nutritious way of eating and providing guidance on weight management will lower blood pressure and blood sugar. The DASH-Life research study will recruit adults with hypertension and type 2 diabetes who live in Baltimore metro areas that don't have many stores selling healthy foods. The DASH-Life research study is 6 months long. Participants will be randomly assigned to one of two groups: 1) Self-Shopping DASH (S-DASH) diet advice group, or 2) Coaching DASH (C-DASH) diet advice group.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Coach-Directed Tailored DASH Groceries Plus Lifestyle Intervention — Participants assigned to the C-DASH group will meet by telephone with the study coach for 1 hour, and then have brief weekly conversations (about 15-30 minutes) by phone during the first three months. During these weekly calls, the study coach will assist participant with selecting fruits, vegetables, nuts, and beans. During months 4-6, the study coach will continue to work with participant to set goals for following the DASH-Life way of eating, but the study will no longer provide a weekly food allowance to purchase groceries.
  • Behavioral: Self-Shopping DASH diet advice — Participants assigned to the S-DASH group will receive a brochure about the DASH eating plan. For the first three months, Participants will also receive a gift card to shop at a local supermarket. During months 4-6, participants will be asked to continue following the DASH eating plan listed in the brochure but will no longer be provided the grocery gift card.

Primary Outcomes

  • Feasibility as assessed by the number of participants enrolled (Baseline)
  • Acceptability as assessed by the Acceptability of the Intervention Measure survey (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-15
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Jessica Yeh, PhD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins University
Contact Information
Study Contact:
Jessica Yeh, PhD
410-614-4316
hyeh1@jhmi.edu
Letitia Thomas
410-281-1600
Letitia Thomas
410-281-1600
lthomas7@jhmi.edu
Johns Hopkins ProHealth Clinical Research Unit
Interventions
  • Behavioral: Coach-Directed Tailored DASH Groceries Plus Lifestyle Intervention — Participants assigned to the C-DASH group will meet by telephone with the study coach for 1 hour, and then have brief weekly conversations (about 15-30 minutes) by phone during the first three months. During these weekly calls, the study coach will assist participant with selecting fruits, vegetables, nuts, and beans. During months 4-6, the study coach will continue to work with participant to set goals for following the DASH-Life way of eating, but the study will no longer provide a weekly food allowance to purchase groceries.
  • Behavioral: Self-Shopping DASH diet advice — Participants assigned to the S-DASH group will receive a brochure about the DASH eating plan. For the first three months, Participants will also receive a gift card to shop at a local supermarket. During months 4-6, participants will be asked to continue following the DASH eating plan listed in the brochure but will no longer be provided the grocery gift card.
Study Locations (1 sites)
Johns Hopkins ProHealth Clinical Research Unit, Baltimore, Maryland 21207 United States
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Diabetes Mellitus Type 2 defined by: self-reported type 2 diabetes diagnosis, or HbA1c\>=6.5%, or treatment of diabetes with diabetes medications(s) * Baseline systolic BP 120-159 mmHg (with or without medications.) * Serum potassium level \>3.0 and \<5 mmol/L, * Estimated glomerular filtration rate (eGFR) \>=45 mL/min/1.73m2. * Willing and able to complete required procedures in English. * Living in Healthy Food Priority Area in Baltimore; the US Department of Agriculture (USDA) defined low income, low access areas, or census blocks with area deprivation index (ADI) 60 and above (State Decile\>=6.) Exclusion Criteria: * Hypoglycemia requiring hospitalization or the assistance of another person in the last 6 months * Cardiovascular event within 6 months * On diabetes or weight loss medications such as glucagon-like peptide 1 (GLP-1), GLP-1/glucose-dependent insulin-releasing peptide (GIP), insulin, or any combination of these medications * HbA1c ≥ 10% * Type 1 diabetes * Baseline systolic BP \< 100 mmHg * Weight \>400 lbs due to the maximum weight on study scale * Chronic disease that might interfere with trial participation * Current participation in another clinical trial that might affect blood pressure, weight loss, diabetes, or ability to adhere to study procedures * Current participation in program with conflicting dietary guidance (i.e., meal replacement or keto diets) * Unwillingness or inability to adopt a DASH-like diet * Planning to leave area in the next 6 months
Conditions Type 2 Diabetes
Phase NA
Enrollment 200
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The JACARDI trial is a multicenter study involving an educational training, with the general objective to improve the eHealth of older adults in relation to the management of type 2 diabetes.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Educational training — The educational training is divided into the following five modules: Module 1: Raising Awareness of eHealth and Health Literacy (Introduction to the aims and context of JACARDI and diabetes); Module 2: Acquiring New Knowledge (Health Literacy and Self-Management of Diabetes); Module 3: Acquiring New Knowledge (Technological and Non-Technological Strategies to Support the Self-Management of Diabetes); Module 4: Practicing New Skills (Usability with Practice Sessions); Module 5: Self-Evaluation and Sustainability of Improvement (Final Questionnaire). The training will be conducted over 10 weeks (one session every other week), with each session lasting an average of 90 minutes.

Primary Outcomes

  • eHealth literacy (Baseline and 10, 14 and 34 weeks later)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-15
Completion: 2026-03-31
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istituto Nazionale di Ricovero e Cura per Anziani
Collaborators: European Union
Principal Investigators:
  • Roberta Bevilacqua (PRINCIPAL_INVESTIGATOR) - IRCCS INRCA, Ancona, Italy
Contact Information
Study Contact:
Anna Rita Bonfigli
0718003719
a.bonfigli@inrca.it
Roberta Papa
AOU Ospedaliera Marche
Massimiliano Petrelli, MD
AOU Ospedaliera Marche
Interventions
  • Other: Educational training — The educational training is divided into the following five modules: Module 1: Raising Awareness of eHealth and Health Literacy (Introduction to the aims and context of JACARDI and diabetes); Module 2: Acquiring New Knowledge (Health Literacy and Self-Management of Diabetes); Module 3: Acquiring New Knowledge (Technological and Non-Technological Strategies to Support the Self-Management of Diabetes); Module 4: Practicing New Skills (Usability with Practice Sessions); Module 5: Self-Evaluation and Sustainability of Improvement (Final Questionnaire). The training will be conducted over 10 weeks (one session every other week), with each session lasting an average of 90 minutes.
Study Locations (2 sites)
AOU Ospedaliera Marche, Ancona, 60127 Italy
IRCCS INRCA Hospital, Ancona, 60127 Italy
Eligibility Criteria
Inclusion Criteria: * Low eHealth literacy (eHeals scale ≤ 29) * No acute or untreated medical problems * Mini Mental State Examination (MMSE) ≥ 24 * Geriatric Depression Scale (GDS) \< 2 Exclusion Criteria: * A myocardial infarction or stroke within 6 months * Painful arthritis, spinal stenosis, amputation, painful foot lesions or neuropathy limiting balance and mobility * Uncontrolled hypertension * Advanced Parkinson's disease or other neuromuscular disorder * Metastatic cancer or immunosuppressive therapy * Significant visual or hearing impairment
Conditions Sleep, Depression Disorders
Phase NA
Enrollment 92
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

1. Research background Residents of nursing homes are chronically ill patients who are placed in long-term homes. Studies have shown that most residents live alone and are prone to loneliness, loss, depression, and anxiety (Lapane et al., 2022). Cranial electrostimulation (CES) can improve anxiety, depression, and sleep, but there are few studies on the cognitive status of patients with chronic mental illness. 2. Research purpose This study uses cranial microcurrent stimulation (CES) to improve cognition, anxiety, depression, sleep and other conditions in patients with chronic mental illness, with the aim of improving their quality of life. 3. Screening criteria for respondents 3.1 Inclusion criteria (Those who meet the following criteria are suitable to participate in this study) 1\. Chronic mental illness patients, 2. Mini-Mental State Examination (MMSE) ≥ 16 points, 3. Education level is junior high school graduates or above, 4. Appropriate oral expression ability, 5. Those who can complete the research consent form, 6. Those who are willing to participate in this study Exclusion conditions (If you have the following conditions, you cannot participate in this study) 1\. Those with obvious risk of violence or suicide; 2. Those with cognitive impairment diagnosed with intellectual disability or autism 4. Research Methods 1. The study was conducted at the Psychiatric Center 2. A total of 92 people were admitted, and they were randomly grouped. 3. This study is a interventional study. Before the intervention, a questionnaire must be filled out, which takes about 30 minutes. Then CES is performed 5 times a week, each time for 40 minutes. After completion, the questionnaire must be filled out again. After 3 months of follow-up, another questionnaire test will be conducted. 4. Possible discomfort and treatment methods During the CES intervention, if you feel dizzy, skin allergies, ear discomfort, or any discomfort, the intervention will be stopped immediately and the medical team will evaluate and treat you. 5. Expected benefits of the study This study uses cranial electrostimulation (CES) to improve cognition, anxiety, depression, sleep and other conditions in patients with chronic mental illness, with the aim of improving their quality of life. 6 Matters that respondents should cooperate with during the research Express your true inner thoughts on the questionnaire content. 7 Confidentiality This study collects data through questionnaires. All identifiable data will be coded to ensure personal data security and case privacy. 8\. Subsidies and Damages Respondents who complete the research data collection will receive a gift voucher worth approximately NT$300

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: CES — Currently, most CES intervention studies are applied to the general public, and a few studies focus on athletic performance. There are no related studies on residents of psychiatric nursing homes, nor are there any research designs for improving cognitive impairment. Therefore, this study explores the use of CES programs to improve the cognition, anxiety, depression, and other conditions of residents of psychiatric care homes, with the goal of improving their quality of life.

Primary Outcomes

  • sleep ("From enrollment to the end of treatment at 12 weeks")
  • Depression ("From enrollment to the end of treatment at 12weeks")
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-20
Completion: 2025-12-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 92 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Liu Hsing Yu
Contact Information
Study Contact:
Hsing yu Liu, master
886+0972909628
hsingyuliu76@gmail.com
Hsing yu liu, master
886+0972909628
hsing yu liu, master
886 +0972909628
hsingyuliu76@gmail.com
Tsaotun Psychiatric Center, MOHW
Interventions
  • Device: CES — Currently, most CES intervention studies are applied to the general public, and a few studies focus on athletic performance. There are no related studies on residents of psychiatric nursing homes, nor are there any research designs for improving cognitive impairment. Therefore, this study explores the use of CES programs to improve the cognition, anxiety, depression, and other conditions of residents of psychiatric care homes, with the goal of improving their quality of life.
Study Locations (1 sites)
Tsaotun Psychiatric Center, MOHW, Nantou City, 542 Taiwan
Eligibility Criteria
Inclusion Criteria: * 1\. Chronic mental illness patients, 2. Mini-Mental State Examination (MMSE) ≥ 16 points, 3. Education level is junior high school graduates or above, 4. Appropriate oral expression ability, 5. Those who can complete the research consent form, 6. Those who are willing to participate in this study Exclusion Criteria: * 1\. Those with obvious risk of violence or suicide 2. People with cognitive impairment who have been diagnosed with mental retardation or autism
Conditions Open Angle Glaucoma (OAG)
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Prospective, randomized, , double-blind, clinical trial, comparing the variation of intraocular pressure (IOP) of patients with mild or moderate primary open-angle glaucoma (OAG) and cataract divided into three groups. All study participants should be treated for the pathology with one or more hypotensive medications or, regardless of the number of drugs, when IOP is greater than 20 mmHg and less than 26 mmHg. The two-year follow-up should also compare the reduction in the number of medications used, reoperation rate, adverse effects, visual acuity, endothelial loss, induction of astigmatism, variation in IOP according to axial diameter of the eye, anterior chamber and age, in addition to the existence of change in the quality of life of patients in the postoperative period

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Procedure: 360º goniotomy assisted transluminal trabeculotomy — Open the Schlemm Canal for 360º with a polipropilen 5-0 suture via trabecular meshwork.
  • Procedure: Phacoemulsification — Cataract Surgery
  • Procedure: 180º gonioscopy assisted transluminal trabeculotomy — Open the Schlemm Canal for 180º with a polipropilen 5-0 suture via trabecular meshwork.

Primary Outcomes

  • Change in intraocular pressure (IOP) after surgery. (From glaucoma medications washout to 2 years after the surgery)
  • Change in the number of glaucoma medications after surgery. (From glaucoma medications washout to 2 years after the surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-07
Completion: 2028-02
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Faculdade de Ciências Médicas de Minas Gerais
Collaborators: Hospital Evangélico de Belo Horizonte
Contact Information
Study Contact:
Daniel F Moura, MD
+5531991055860
dfmoftalmo@gmail.com
Bruno L Trindade, PhD
+553132487450
bruno.trindade@feluma.org.br
Instituto de Olhos Ciências Médicas - Faculdade de Ciências Médicas de Minas Gerais
Interventions
  • Procedure: 360º goniotomy assisted transluminal trabeculotomy — Open the Schlemm Canal for 360º with a polipropilen 5-0 suture via trabecular meshwork.
  • Procedure: Phacoemulsification — Cataract Surgery
  • Procedure: 180º gonioscopy assisted transluminal trabeculotomy — Open the Schlemm Canal for 180º with a polipropilen 5-0 suture via trabecular meshwork.
Study Locations (1 sites)
Instituto de Olhos Ciências Médicas - Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Minas Gerais 30150270 Brazil
Eligibility Criteria
Inclusion Criteria: * Patients aged 40 years or older, * Previously included in the glaucoma departments of the participating institutions, * Indication for cataract surgery, diagnosed by clinical examination with visual acuity (VA) equal to or worse than 20/40, * Primary Open Angle Glaucoma (POAG), determined by the presence of typical visual field (VF) defects and/or by the aspect of the optic nerve observed at fundoscopy or retinography (increased vertical optical excavation with thinning of the neural rhyme, asymmetry of the cup/disc ratio greater than 0.2, localized loss ("notch") or defect in the retinal nerve fiber layer ("Hoyt")). * APIC classification with amplitude greater/equal to 2 and pigmentation less than 4 on gonioscopy. * Intraocular pressure (IOP) less than or equal to 25 mmHg before washout of hypotensive eye drops. * IOP between 22 and 30 mmHg after washout of hypotensive eye drops or with a history of IOP greater than or equal to 21 mmHg in more than one previous care described in the medical record. Exclusion Criteria: Patients who have any of the following situations: * Severe glaucoma, determined according to the Hoddap-Parrish-Anderson criteria; * Axial diameter greater than 26 mm or less than 21.00 mm; * Endothelial count less than 1500 cc; * Pachymetry less than 480 or greater than 600 microns; * Patients undergoing some type of intraocular surgery or laser procedure in the preoperative period and/or after these procedures in the postoperative period; * Those who present some important per-operative complication during the study. * With high risk of progression, the so-called rapid progressors, who are patients with high IOPs even with the use of many medications, regardless of the severity of the nerve injury.
Conditions Breast Cancer, HER2-positive Breast Canc...
Phase PHASE1
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HER2 Vaccine — MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines

Primary Outcomes

  • Evaluation of safety and toxicity at regular intervals by NCI common toxicity criteria 5.0 (through completion of 3 vaccine series (i.e. up to day 64 post final vaccine injection))
  • Immune Response (through completion of 3 vaccine series (i.e. up to day 64 post final vaccine injection))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-09
Completion: 2030-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pravin T.P Kaumaya
Principal Investigators:
  • Pravin Kaumaya, PhD (PRINCIPAL_INVESTIGATOR) - Indiana University
Contact Information
Study Contact:
Niraj Shah
317-278-3420
shahnir@iu.edu
Niraj Shah
317-278-3420
shahnir@iu.edu
Indiana University Melvin & Bren Simon Comprehensive Cancer Center
Pravin Kaumaya, PhD
Indiana University Melvin & Bren Simon Comprehensive Cancer Center
Interventions
  • Drug: HER2 Vaccine — MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines
Study Locations (1 sites)
Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana 46202 United States
Eligibility Criteria
Inclusion Criteria: 1. ≥ 18 years old at the time of informed consent 2. Ability to provide written informed consent and HIPAA authorization CTO-IUSCC-0864 3. Histologically confirmed HER2 positive breast cancer 1. Any Estrogen Receptor/Progesterone Receptor status is allowed. 2. HER2 positive is defined as HER2 3+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of \> 2.0 or \> 6 total HER2 gene copies per cell. 4. High-risk disease defined as one of the following: 1. Any residual invasive carcinoma in the breast or axillary nodes in the final pathology from resected tumor following neoadjuvant taxane and trastuzumab-based chemotherapy 2. Inflammatory phenotype at the time of diagnosis per the treating physician 3. Clinical stage III disease at the time of diagnosis per the treating physician and/or clinical imaging 4. Locally recurrent disease and have undergone definitive local therapy 5. Received at least six months of HER2 targeted therapy with trastuzmab +/- pertuzumab TDM-1, or others in the neoadjuvant or adjuvant setting a. Any combination of HER2 targeted therapy in the curative setting is allowed, including neratinib or others on a clinical trial 6. Completed last dose of HER2 targeted therapy no more than 6 months prior to registration 7. Completed last dose of cytotoxic chemotherapy or radiation at least 30 days prior to registration with resolution of any prior toxicity to ≤ 2 with the exception of alopecia 8. ECOG performance status of 0 to 2 9. Adequate organ function as indicated by: 1. Total bilirubin \< 1.5 mg/dL (except in patients with documented Gilbert's disease, who must have a total bilirubin \< 3.0 mg/dL) 2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.0 x ULN 3. Calculated creatinine clearance of \> 60 mL/min using the Cockcroft-Gault formula 4. Absolute neutrophil count (ANC) \> 1.0 K/mm3 5. Platelets \> 100 K/ mm3 10. Adequate cardiac function defined as left ventricular ejection fraction (LVEF) above the institutional lower limit of normal by echocardiogram or MUGA obtained within 90 days of registration 11. Women of childbearing potential must have a negative serum pregnancy test within 14 days of protocol registration. Women are considered to have childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) unless they meet one of the following criteria: 1. Has undergone a hysterectomy or bilateral oophorectomy; or 2. Has been naturally amenorrheic for at least 12 consecutive months. 12. Women of childbearing potential and men must agree to use one effective contraception throughout the study and for 6 months after the last study treatment. Note: Acceptable methods of birth control include abstinence, partner with previous vasectomy, placement of an intrauterine device (IUD), condom with spermicidal foam/gel/film/cream/suppository, diaphragm or cervical vault cap, or hormonal birth control (pills or injections). Exclusion Criteria: 1. Any distant disease recurrence. 2. Patients with active malignancy other than breast cancer. Note: Patients with prior malignancies without recurrence after standard treatment will not be excluded. 3. Patients receiving or planned to receive adjuvant CDK4/6 inhibitor therapy 4. Patients who are {MVF-HER-2(266-296) and MVF-HER-2 (597-626)} immediate hypersensitivity skin test positive. 5. Patients who require or likely to require corticosteroids or other immunosuppressives 6. Patients with active autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis dermato-myositis, or a vasculitic syndrome. Note: At the discretion of the treating physician, patients who show disease control for at least 6 months and do not require immunosuppressives may be enrolled. 7. Patients who have developed anaphylactic responses to other vaccines. 8. Patients who have evidence of active infection that requires antibiotic therapy. Patients must have been off antibiotic treatment for at least 3 weeks prior to initiating treatment and must be confirmed to be clear of the infection. 9. Known seropositive or active viral infection with human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV). Seropositivity due to vaccination are eligible. 10. Uncontrolled illness that would limit safety or compliance with study procedures including, but not limited to, active infection, congestive heart failure, unstable angina, or cardiac arrhythmia. 11. Patients with serious uncontrolled cardiopulmonary disorders, including congestive heart failure, symptomatic coronary artery disease, serious cardiac arrhythmia, and symptomatic chronic obstructive pulmonary disease or patients with other serious uncontrolled medical diseases. At the discretion of the treating physician, patients who show disease control for at least 6 months may be enrolled. 12. History of splenectomy 13. Pregnant or breast feeding.
Conditions Diabetes
Phase NA
Enrollment 44
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To investigate if there is a significant effect of manual diaphragmatic release technique on exercise capacity, sleep quality, chest expansion, ADL, fatigue and quality of life in older adults with type II diabetes.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: manual diaphragm release technique — The participant should be supine with relaxed limbs, and the therapist should position themselves at the head, making manual contact with the pisiform, hypothenar region, and fingers. The therapist should gently pull the contact towards the head, deepen it during exhalation, and gradually increase the depth.
  • Other: deep breathing exercises — Participants in a crook laying position are instructed to inhale through the nose, lift the abdomen, and let out through the mouth, breathing six breaths per minute for 30 minutes.

Primary Outcomes

  • 6-minute walk test (up to 6 weeks)
  • Pittsburgh Sleep Quality Index (PSQI) (up to 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-30
Completion: 2026-10
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: false
Enrollment: 44 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beni-Suef University
Contact Information
Study Contact:
Mohammed Yo Elhamrawy, Ph.D
+201282805567
dr_melhamrawy@yahoo.com
Mohammed YO Elhamrawy, PHD
Beni suef hospital
Interventions
  • Other: manual diaphragm release technique — The participant should be supine with relaxed limbs, and the therapist should position themselves at the head, making manual contact with the pisiform, hypothenar region, and fingers. The therapist should gently pull the contact towards the head, deepen it during exhalation, and gradually increase the depth.
  • Other: deep breathing exercises — Participants in a crook laying position are instructed to inhale through the nose, lift the abdomen, and let out through the mouth, breathing six breaths per minute for 30 minutes.
Study Locations (1 sites)
Beni suef hospital, Banī Suwayf, 62511 Egypt
Eligibility Criteria
Inclusion Criteria: * History of Diabetes Type II for more than one year. * They will be well controlled with HbA1c≤7. * Patients will be aged from 55 years and above and had a body mass index less than 30 kg/m². * Patients will follow up on the training program and instructions. They will be medically stable. Exclusion Criteria: * Chest diseases. * Diaphragmatic hernia, clinical evidence of phrenic nerve injury, recent abdominal or thoracic surgery, or history of traumatic lesion possibly affecting diaphragm. * History of Myocardial infarction and/or cardiothoracic surgery * Unstable medical status. * Cognitive disability hindering responding to the questionnaires.
Conditions Breast Neoplasm Female, Early Detection ...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to test the impact of a multilevel decision support intervention on informed decisions about breast MRI among high-risk Black and Latina women. Participants (N=80) will be randomized to (1) enhanced usual care (risk assessment + referral to nurse practitioner) or (2) decision support (enhanced usual care + decision aid). Assessments will take place at baseline (T0) and 1-month post-intervention (T1). The primary outcome is informed decisions about breast MRI at T1.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Behavioral: Enhanced Usual Care — Risk assessment and notification, referral to nurse practitioner (NP) at the Ralph Lauren Center (RLC)
  • Behavioral: Decision Support — The decision aid describes two different breast cancer screening plans: (1) annual mammography only; and (2) annual mammography plus annual breast MRI. The decision aid provides balanced information about breast MRI, including its risks, limitations, and benefits.

Primary Outcomes

  • Informed decisions about breast MRI (1 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-01
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Georgetown University
Principal Investigators:
  • Claire C. Conley, PhD (PRINCIPAL_INVESTIGATOR) - Georgetown University
Contact Information
Study Contact:
Claire C. Conley, PhD
2026875086
claire.conley@georgetown.edu
Claire C. Conley, PhD
202-687-5086
claire.conley@georgetown.edu
Georgetown University
Claire C. Conley, PhD
Georgetown University
Interventions
  • Behavioral: Enhanced Usual Care — Risk assessment and notification, referral to nurse practitioner (NP) at the Ralph Lauren Center (RLC)
  • Behavioral: Decision Support — The decision aid describes two different breast cancer screening plans: (1) annual mammography only; and (2) annual mammography plus annual breast MRI. The decision aid provides balanced information about breast MRI, including its risks, limitations, and benefits.
Study Locations (1 sites)
Georgetown University, Washington D.C., District of Columbia 20007 United States
Eligibility Criteria
Inclusion Criteria: * female * aged 18-74 years * self-identifying as Black and/or Latina * no personal history of breast cancer * English- or Spanish-speaking * having received a mammogram with normal results in the last 12 months * ≥20% lifetime breast cancer risk per the NCI Breast Cancer Risk Assessment Tool (BCRAT) Exclusion Criteria: * aged \<18 or ≥75 * pregnancy

ASTHMAXcel Voice Study

NCT06935084
Recruiting
Conditions Asthma
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to conduct a randomized controlled trial (RCT) to compare the adapted and refined ASTHMAXcel Voice platform to usual care (UC). It is hypothesized by the investigator team that ASTHMAXcel Voice will be associated with improved clinical and process outcomes, asthma quality of life (QOL), medication adherence, and self-efficacy as compared to UC.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: ASTHMAXcel Voice platform — ASTHMAXcel Voice is a mobile health application with a multi-level approach to address barriers with intervention components and facilitate health behavior change through the use of push notifications and interactive educational content.

Primary Outcomes

  • Change in Asthma Control (Change from Baseline to 6 months after randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-18
Completion: 2028-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Montefiore Medical Center
Collaborators: Yeshiva University, Agency for Healthcare Research and Quality (AHRQ)
Principal Investigators:
  • Sunit Jariwala, MD (PRINCIPAL_INVESTIGATOR) - Montefiore Medical Center
Contact Information
Study Contact:
Sunit Jariwala, MD
609-937-1023
sjariwal@montefiore.org
Juliana D Rodriguez, MD
718-862-1722
juliana.rodríguez@einsteinmed.edu
Sunit Jariwala, MD
609-937-1023
sjariwal@montefiore.org
Montefiore Medical Center
Interventions
  • Other: ASTHMAXcel Voice platform — ASTHMAXcel Voice is a mobile health application with a multi-level approach to address barriers with intervention components and facilitate health behavior change through the use of push notifications and interactive educational content.
Study Locations (1 sites)
Montefiore Medical Center, The Bronx, New York 10467 United States
Eligibility Criteria
Inclusion Criteria: * English speaking * Persistent asthma (diagnosed by a healthcare provider) on a daily controller medication * Able to provide informed consent * Smartphone access (iOS or Android) with data plan Exclusion Criteria: * Pregnancy * Severe psychiatric or cognitive problems that would prohibit completion of protocol